Abstract
Making accurate diagnosis of Alzheimer’s disease (AD) is crucial for effective treatment and management. Although deep learning has been applied to AD classification, it is typically performed at group level, the data used are not sufficiently heterogeneous and comprehensive, and decision confidence is not evaluated at individual (single patient) level. This paper proposed a more practical deep learning approach that not only detects AD stages of individuals, but also provides its corresponding confidence estimation. In particular, in addition to a convolutional neural network (CNN), we incorporated a softmax confidence metric based on the network’s output activity to evaluate its classification confidence. Further, we applied this approach to a heterogeneous and comprehensive data that comprised cognitive and functional assessments, tau-PET and MRI neuroimaging, medical/family history, demographic, and APoE genotype. Importantly, we utilised leave-one-out cross-validation to train the CNN and classify an individual’s healthy control, mild cognitive impairment or AD state, while concurrently estimating each output decision’s confidence. We showed that, over different confidence softmax temperature values, CNN could attain classification accuracies at 83-85% for the three classes while having robust confidence scores of 78-83%. Further improvement in confidence breakdown was achieved using the optimal temperature value in confidence evaluation, with higher confidence scores for correct than error decisions. Overall, the computed classification confidence of an individual may aid clinicians and other stakeholders in understanding the reliability of the model’s decision outcome and offer better trust. The implication of this work may extend to other classification applications, in which the confidence level of a single deep learning-based decision can be evaluated.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Code repository is available at https://github.com/Afolabialausa/Alzheimer-s-Disease-Classification-.git The original ADNI dataset was not included as part of this reposi-tory. Requests to access the original datasets should be directed to ADNI (http://adni.loni.usc.edu/).
https://github.com/Afolabialausa/Alzheimer-s-Disease-Classification-.git